- Home
- NXE vs ADMA Comparison
NXE vs ADMA Comparison
Compare NXE & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXE
- ADMA
- Stock Information
- Founded
- NXE N/A
- ADMA 2004
- Country
- NXE Canada
- ADMA United States
- Employees
- NXE N/A
- ADMA N/A
- Industry
- NXE
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXE
- ADMA Health Care
- Exchange
- NXE Nasdaq
- ADMA Nasdaq
- Market Cap
- NXE 4.3B
- ADMA 4.1B
- IPO Year
- NXE N/A
- ADMA N/A
- Fundamental
- Price
- NXE $6.86
- ADMA $16.02
- Analyst Decision
- NXE
- ADMA Strong Buy
- Analyst Count
- NXE 0
- ADMA 4
- Target Price
- NXE N/A
- ADMA $21.25
- AVG Volume (30 Days)
- NXE 7.0M
- ADMA 2.5M
- Earning Date
- NXE 03-06-2025
- ADMA 02-26-2025
- Dividend Yield
- NXE N/A
- ADMA N/A
- EPS Growth
- NXE N/A
- ADMA N/A
- EPS
- NXE 0.20
- ADMA 0.28
- Revenue
- NXE N/A
- ADMA $382,809,000.00
- Revenue This Year
- NXE N/A
- ADMA $67.03
- Revenue Next Year
- NXE N/A
- ADMA $14.58
- P/E Ratio
- NXE $35.84
- ADMA $57.15
- Revenue Growth
- NXE N/A
- ADMA 63.39
- 52 Week Low
- NXE $4.95
- ADMA $4.86
- 52 Week High
- NXE $8.96
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- NXE 43.26
- ADMA 35.94
- Support Level
- NXE $6.61
- ADMA $15.92
- Resistance Level
- NXE $6.98
- ADMA $17.32
- Average True Range (ATR)
- NXE 0.31
- ADMA 0.88
- MACD
- NXE 0.01
- ADMA -0.15
- Stochastic Oscillator
- NXE 28.63
- ADMA 3.00
About NXE Nexgen Energy Ltd.
NexGen Energy Ltd is a mineral exploration company. It is engaged in the acquisition, exploration, evaluation and development of uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin. The Rook I property hosts the world-class Arrow Zone, the Bow discovery. as well as the discovered Harpoon area located northeast of the Arrow deposit.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.